# Aldeyra Therapeutics, Inc.: overview ALDX · Nasdaq · CIK 1341235 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aldx.md) · [Financials](/companies/aldx/financials.md) · [Filings](/companies/aldx/filings.md) · [Insiders](/companies/aldx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-266989.md) | not reported | [(0.17)](/filings/0001341235-26-000006.md) | [(0.16)](/filings/0001341235-26-000010.md) | [(0.13)](/filings/0001193125-25-266989.md) | not reported | [(0.06)](/filings/0001341235-26-000006.md) | [(0.09)](/filings/0001341235-26-000010.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.07)](/filings/0000950170-23-006998.md) | [(1.06)](/filings/0000950170-24-027933.md) | [(0.64)](/filings/0000950170-25-030102.md) | [(0.94)](/filings/0001193125-26-083012.md) | [(0.56)](/filings/0001193125-26-083012.md) | | Free cash flow | $m | [(42.6)](/filings/0000950170-23-006998.md) | [(56.7)](/filings/0000950170-24-027933.md) | [(30.3)](/filings/0000950170-25-030102.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aldx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Knoll Capital Management, LLC](/funds/1325083.md) | 2026-06-30 | $11.7m | 5,475,516 | | Unchanged | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $8.0m | 3,751,558 | | Added +921,683 | | [KINGDON CAPITAL MANAGEMENT, L.L.C.](/funds/1000097.md) | 2026-06-30 | $5.6m | 2,652,315 | | Added +500,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.0m | 2,361,796 | | Reduced −1,946 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $4.1m | 1,940,338 | | Added +536,348 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.2m | 1,506,974 | | Added +1,377,281 | | [683 Capital Management, LLC](/funds/1404574.md) | 2026-06-30 | $3.1m | 1,450,000 | | Reduced −50,000 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.9m | 1,375,115 | | Added +406,224 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.7m | 1,257,243 | | Reduced −2,506,644 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $2.4m | 1,128,803 | | Added +1,041,725 | ## Recent filings [All 637 filings](/companies/aldx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 03:01 ET | [8-K](/filings/0001193125-26-405954.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-405954 | | 2026-08-06 | 16:02 ET | [10-Q](/filings/0001341235-26-000010.md) | Quarterly report, period 2026-06-30 | 0001341235-26-000010 | | 2026-07-30 | 17:07 ET | [8-K](/filings/0001193125-26-326337.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-326337 | | 2026-07-15 | 16:46 ET | [8-K](/filings/0001193125-26-304880.md) | 8.01 Other events | 0001193125-26-304880 | | 2026-06-10 | 20:30 ET | [8-K](/filings/0001193125-26-264514.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-264514 | | 2026-05-07 | 16:02 ET | [10-Q](/filings/0001341235-26-000006.md) | Quarterly report, period 2026-03-31 | 0001341235-26-000006 | | 2026-05-01 | 08:00 ET | [8-K](/filings/0001193125-26-199157.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-199157 | | 2026-04-27 | 16:10 ET | [DEF 14A](/filings/0001193125-26-182099.md) | Proxy statement, period 2025-06-10 | 0001193125-26-182099 | | 2026-04-20 | 17:00 ET | [8-K](/filings/0001193125-26-164198.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-164198 | | 2026-04-01 | 16:25 ET | [8-K](/filings/0001193125-26-137984.md) | 8.01 Other events | 0001193125-26-137984 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-083012.md), filed Feb 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1341235 - Tickers: ALDX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.